Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2009 - 2026)

Alnylam Pharmaceuticals has reported Accumulated Expenses for 18 years, with the latest figure at $946.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 34.41% year-over-year to $946.5 million; the trailing twelve-month figure through Mar 2026 stood at $946.5 million (up 34.41% YoY), and the FY2025 full-year result was $1.1 billion, up 36.1% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $946.5 million, down from $1.1 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $1.2 billion in Q3 2025, with the low at $355.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $730.4 million across 5 years, with a median of $713.0 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 42.89% — and 2025, when it advanced 0.76%.
• Alnylam Pharmaceuticals' Accumulated Expenses stood at $545.5 million in 2022, then surged by 30.72% to $713.0 million in 2023, then grew by 11.32% to $793.7 million in 2024, then soared by 36.1% to $1.1 billion in 2025, then declined by 12.38% to $946.5 million in 2026.
• The last three Accumulated Expenses figures came in at $946.5 million (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.